Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-44.0,  Hemorrhagic Fever, Ebola Healthy A volunteer must meet all of the following 1. 18 to 44 years old. 2. Available for follow-up for the duration of the study (12 months). 3. Able to provide proof of identity to the acceptance of the study clinician completing the enrollment process. 4. Completion of an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly. 5. Able and willing to complete the informed consent process. 6. Willing to receive HIV test results and willing to abide by NIH guidelines for partner notification of positive HIV results. 7. Willing to donate blood for sample storage. 8. In good general health without clinically significant medical history. 9. Physical examination and laboratory results without clinically significant findings within the 28 days prior to enrollment. Laboratory within 28 days prior to enrollment: 10. Hematocrit equal to 34% for women; 38% for men. 11. Normal fibrinogen levels, D-dimer immunoassay less than 2.0 microg/mL, and RBC morphology without evidence of microangiopathic hemolysis. 12. WBC count: Non-African Americans: equal to 3,300-12,000 cells/mm3, African-Americans: equal to 2,500 000 cells/mm3 (in the absence of clinical or pathological etiology). 13. Differential either within institutional normal range or accompanied by site physician approval. 14. Total lymphocyte count: Non-African Americans: equal to 800 cells/mm3, African Americans: equal to 650 cells/mm3 (in the absence of clinical or pathological etiology) 15. Platelets within institutional normal limits. 16. Prothrombin time and activated partial thromboplastin time (PT, PTT) within institutional normal range. 17. Alanine aminotransferase (ALT) (also called SGPT) = upper limit of normal range 18. Serum creatinine = upper limit of normal range 19. Negative Food and Drug Administration (FDA)-approved HIV blood test 20. Negative hepatitis B surface antigen (HbsAg) 21. Negative antibody to hepatitis C virus (anti-HCV), or negative HCV PCR if the anti-HCV is positive. 22. Normal urinalysis defined as negative glucose, negative or trace protein, and negative hemoglobin by dipstick. Female-Specific 23. Negative pregnancy test (urine or serum) for women presumed to be of reproductive potential. 24. A female participant must meet one of the following No reproductive potential because of menopause (one year without menses) or because of a hysterectomy, bilateral oophorectomy, or tubal ligation, or Participant agrees to be heterosexually inactive at least 21 days prior to enrollment and throughout the duration of the study, or Participant agrees to consistently practice contraception at least 21 days prior to enrollment and throughout the duration of the study by one of the following methods condoms, male or female, with or without a spermicide diaphragm or cervical cap with spermicide intrauterine device contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method male partner has previously undergone a vasectomy for which there is documentation  A volunteer will be excluded if one or more of the following conditions apply. Women: 1. Breast-feeding. Volunteer has received any of the following substances: 2. Immunosuppressive or cytotoxic medications within the past six months with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis 3. Blood products within 120 days prior to HIV screening. 4. Immunoglobulin within 60 days prior to HIV screening. 5. Live attenuated vaccines within 30 days prior to initial study injection. 6. Investigational research agents within 30 days prior to initial study injection. 7. Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 14 days prior to initial study injection. 8. Current anti-TB prophylaxis or therapy. Volunteer has a history of any of the following clinically significant conditions: 9. Serious adverse reactions to vaccines, such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain. 10. Autoimmune disease or immunodeficiency. 11. Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids. 12. Diabetes mellitus (type I or II), with the exception of gestational diabetes. 13. Thyroid disease including history of thyroidectomy and diagnoses that required medication within the past 12 months. 14. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years. 15. Hypertension that is not well controlled by medication or is more than 145/95 at enrollment. 16. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws. 17. Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study. 18. Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years. 19. Asplenia or any condition resulting in the absence or removal of the spleen. 20. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled by medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment 21. Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence or a volunteer's ability to give informed consent